Octreotide
1
Reactions 1264 - 8 Aug 2009 S Octreotide Thrombocytopenia: case report A 53-year-old man developed acute, reversible thrombocytopenia during treatment with octreotide [Sandostatin] for management of portal hypertension with upper gastrointestinal bleeding. The man received an IV octreotide 50µg bolus, followed by 50 µg/h infusion. His platelet count had decreased to 75 000/mm 3 about 4 hours after bolus administration, and despite multiple platelet transfusions, it dropped to 4 000/mm 3 over the next 50 hours. Octreotide was not suspected as the cause of thrombocytopenia, and he continued to receive the octreotide infusion for a total of 72 hours. His platelet count gradually increased after the octreotide infusion was discontinued, and he was discharged on hospital day 5 with a platelet count of 28 000/mm 3 . He was readmitted to hospital 3 weeks later, with recurrent variceal bleeding. His platelet count was 214 000/mm 3 . The man inadvertently received octreotide, and his platelet count dropped to 89 000/mm 3 . Octreotide was discontinued, and after discharge, his platelet count increased to 221 000/mm 3 . Author comment: "Our case is highly suggestive of sandostatin as the etiology of drug-induced reversible thrombocytopenia." Chisholm S, et al. Sandostatin causing reversible thrombocytopenia. European Journal of Gastroenterology and Hepatology 21: 474-475, No. 4, Apr 2009 - USA 801146868 1 Reactions 8 Aug 2009 No. 1264 0114-9954/10/1264-0001/$14.95 © 2010 Adis Data Information BV. All rights reserved
-
Upload
truongtuong -
Category
Documents
-
view
213 -
download
0
Transcript of Octreotide
Reactions 1264 - 8 Aug 2009
SOctreotide
Thrombocytopenia: case reportA 53-year-old man developed acute, reversible
thrombocytopenia during treatment with octreotide[Sandostatin] for management of portal hypertension withupper gastrointestinal bleeding.
The man received an IV octreotide 50µg bolus, followedby 50 µg/h infusion. His platelet count had decreased to75 000/mm3 about 4 hours after bolus administration, anddespite multiple platelet transfusions, it dropped to4 000/mm3 over the next 50 hours. Octreotide was notsuspected as the cause of thrombocytopenia, and hecontinued to receive the octreotide infusion for a total of72 hours.
His platelet count gradually increased after theoctreotide infusion was discontinued, and he wasdischarged on hospital day 5 with a platelet count of28 000/mm3. He was readmitted to hospital 3 weeks later,with recurrent variceal bleeding. His platelet count was214 000/mm3.
The man inadvertently received octreotide, and hisplatelet count dropped to 89 000/mm3. Octreotide wasdiscontinued, and after discharge, his platelet countincreased to 221 000/mm3.
Author comment: "Our case is highly suggestive ofsandostatin as the etiology of drug-induced reversiblethrombocytopenia."Chisholm S, et al. Sandostatin causing reversible thrombocytopenia. EuropeanJournal of Gastroenterology and Hepatology 21: 474-475, No. 4, Apr 2009 -USA 801146868
1
Reactions 8 Aug 2009 No. 12640114-9954/10/1264-0001/$14.95 © 2010 Adis Data Information BV. All rights reserved
![BS 499 Part 1 [1965]](https://static.fdocuments.nl/doc/165x107/54081862dab5cac8598b460a/bs-499-part-1-1965.jpg)
